Needham Reiterates Buy on Solid Biosciences, Maintains $19 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

Needham analyst Gil Blum reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $19 price target.

Comments

No comments yet. Be the first!